Glaucoma News

VILAMOURA, Portugal — An AI algorithm based on the Corvis ST dynamic corneal response parameters showed the ability to predict glaucomatous visual field progression 1 month after treatment with prostaglandin analogs.

Individuals with a high polygenic risk were more likely to experience rapid structural and functional progression in early-stage glaucoma, despite receiving intensive treatment, researchers reported in JAMA Ophthalmology.

Optometrists should adopt a holistic treatment approach and consider ocular, systemic and environmental risk factors that affect glaucoma development and progression, according to a review in the Journal of Current Glaucoma Practice.

VILAMOURA, Portugal — At the ESCRS winter meeting, Norbert Koerber, MD, PhD, presented the 5-year data of ab interno canaloplasty in patients with primary open-angle glaucoma.

Treating but not overtreating hypertension is key in patients with glaucoma, according to a speaker.

The combination of low diastolic blood pressure and high IOP in patients with moderate to advanced glaucoma was associated with faster ganglion cell complex thinning rates, according to a study.

In this Healio Video Perspective, Nathan M. Radcliffe, MD, outlines why MicroPulse transscleral laser therapy is a viable option for patients who are not suitable for or do not want traditional glaucoma surgery.

In this Healio Video Perspective from the American Glaucoma Society meeting, Thomas W. Samuelson, MD, discusses positive safety and efficacy data for the ViaLase femtosecond laser image-guided high-precision trabeculotomy treatment.

Sight Sciences launched the Ergo-Series of its Omni surgical system for minimally invasive glaucoma surgery in the United States.

Femtosecond laser image-guided high-precision trabeculotomy, or FLigHT, for primary open-angle glaucoma showed positive safety and efficacy results in a first-in-human study, according to a press release from ViaLase.